CENTERS FOR DISEASE CONTROL. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men—New York City and California. Morbid Mortal Wkly Rep1981; 25: 305–8.
FauciASMasurHGelmannEPMarkhamPDHahnBHLaneHC. The acquired immunodeficiency syndrome: An update. Ann Intern Med1985; 102: 800–13.
4.
GottliebMSGroopmanJEWeinsteinWMFaheyJLDetelsR. The acquired immunodeficiency syndrome. Ann Intern Med1983; 99: 208–20.
5.
LaneHCDepperJMGreeneWC. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome: Evidence for a selective defect in soluble antigen recognition. N Engl J Med1985; 313: 79–84.
6.
CENTERS FOR DISEASE CONTROL. Provisional Public Health Service interagency recommendations for screening donated blood and plasma for antibody to the virus causing acquired immunodeficiency syndrome. Morbid Mortal Wkly Rep1985; 34: 1–5.
7.
LaneHCMasurHLongoDL. Partial immune reconstitution in a patient with the acquired immunodeficiency syndrome. N Engl J Med1984; 311: 1099–103.
8.
RookAHMasurHLaneHC. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest1983; 72: 398–403.
9.
LaneHCSiegalJRookAH. Use of interleukin-2 in patients with the acquired immunodeficiency syndrome (AIDS). J Biol Response Modifiers1984; 3: 512–6.
10.
LaneHCMasurHGelmannEPFauciAS. Therapeutic approaches to patients with AIDS. Cancer Res1985; 45 (suppl): 4674–6.
11.
MitsuyaHPopovicMYarchoanRMatsushitaSGalloRCBroderS. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science1984; 226: 172–4.
12.
MitsuyaHMatsushitaSHarperMEBroderS. Pharmacological inhibition of infectivity of HTLV-III in vitro. Cancer Res1985; 45 (suppl): 4583–7.
13.
McCormickJBGetchellJPMitchellSWHicksDR. Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes. Lancet1984; 2: 1367–9.
14.
SandstromEGKaplanJCByingtonREHirschMS. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet1985; 1: 1480–2.
15.
AblashiDVTwardzikDREastonJM. Effects of 5-tungsto-2-antimoniate in oncogenic DNA and RNA virus-cell systems. Eur J Cancer1977; 13: 713–20.
